For a free, confidential legal consultation, submit your Product Liability injury claim or call 1-800-471-3980 now.
If you are looking for a firm that can handle Product Liability lawsuits, or are simply unsure if you have a case, there is no obligation to discuss your case with one of GPW's attorneys. Contact us today.
March 14th, 2007. (Press Release) The U.S. Food and Drug Administration (FDA) has requested that all manufacturers of sedative-hypnotic drug products, a class of drugs used to induce and/or maintain sleep, strengthen their product labeling to include stronger language concerning potential risks. These risks include severe allergic reactions and complex sleep-related behaviors, which may include ... [More >>]
July 28th, 2006. Injured by Zyprexa? Side effects of this antipsychotic drug include diabetes, weight gain, hyperglycemia, pancreatitis, and diabetic ketoacidosis. Zyprexa Risks The following are the risks and side effects associated with Zyprexa therapy. This list is not exhaustive. From the FDA web site, Zyprexa's risks include: A life-threatening nervous system ... [More >>]
May 18th, 2006. 5/5/06 - FDA Updates Regarding Voluntary Market Withdrawal of Bausch & Lomb ReNu MoistureLoc® Contact Lens Solution 4/13/06 - Bausch & Lomb Asks Retailers to Remove U.S.-Manufactured ReNu® with MoistureLoc® from Shelves; and Recommends Consumers Switch to Another Solution Pending Investigation of Reports of Fusarium Infections Among ... [More >>]
May 5th, 2006. (Press Release) Update on Serious Eye Infections Associated With Soft Contact Lens Use and Contact Lens Solution May 5, 2006. As reported in the MMWR, patients with confirmed cases of Fusarium keratitis have reported using various contact lens cleaning solutions including various types of ReNu products and generics. We continue to confirm reported ... [More >>]
April 14th, 2006. (Press Release) Bausch & Lomb (NYSE:BOL) today asked U.S. retailers to remove ReNu® with MoistureLoc® from their shelves temporarily, and recommended that consumers switch to another lens care solution for the time being, until the investigation of reports of fungal keratitis infections among contact lens wearers in the United States is ... [More >>]
December 9th, 2005. An editorial appearing Thursday December 9, 2005 in The New England Journal of Medicine called into question the information provided by Merck for a key study about cardiovascular events caused by the arthritis drug Vioxx. The study called into question was published in November of 2000 for the VIGOR ... [More >>]
August 19th, 2005. Have a Vioxx legal claim? For a free, confidential legal consultation, Submit your Vioxx injury claim or call 1-800-471-3980 now. Of Note: Actual damages: $24.4 Million Punitive Damages: $229 Million $229 Million is the amount Merck made in sales of Vioxx from Oct. 2001, when FDA suggested the label change, to the ... [More >>]
June 9th, 2005. (Press Release) Eli Lilly and Company announced today that it has entered into an agreement in principle with plaintiffs' attorneys involved in Zyprexa liability litigation to settle a majority of the claims against Lilly relating to the medication. When finalized, the settlement will resolve the majority ... [More >>]
April 11th, 2005. (Press Release) The Food and Drug Administration (FDA) today issued a public health advisory to alert health care providers, patients, and patient caregivers to new safety information concerning an unapproved (i.e., “off-label”) use of certain drugs called “atypical antipsychotic drugs.” These drugs are approved for the treatment of schizophrenia and mania, but ... [More >>]
April 7th, 2005. (Press Release) The Food and Drug Administration (FDA) today announced a series of important changes pertaining to the marketing of the non-steroidal anti-inflammatory class of drugs, including COX-2 selective and prescription and non-prescription (over-the-counter (OTC)) non-selective NSAID medications. A list of these products is available on the FDA web site. ... [More >>]
You are currently browsing GPW's archives for the Product Liability category.
